Are there alternative treatments to eculizumab for aHUS?

600mg weekly for the first 4 weeks, followed by 900mg for the fifth dose 1 week later, then 900mg every 2 weeks thereafter. Jan 23, 2024 ... This trial was a phase 3, patient-blinded, randomized control study assessing the impact of eculizumab on the course of acute renal failure in patients with ... About This Drug. Eculizumab-xxxx (Soliris, Bkemv) is used to treat some blood disorders and nerve disorders. It is given in the vein (IV). View the fact sheet ... Nov 14, 2024 ... The brand names of the eculizumab biosimilars are Bekemv and Epysqli. They are only available for the treatment of PNH and aHUS in countries which have ... May 28, 2024 ... The US Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare ... See full prescribing information for Soliris. Soliris™ (eculizumab),. Concentrated solution for intravenous infusion. Initial U.S. Approval: 2007. WARNING: ... Sep 29, 2023 ... What are the side effects of Soliris? · headache · diarrhea · high blood pressure (hypertension) · common cold (upper respiratory infection ) ... Mar 15, 2025 ... The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to ... Initially 900 mg once weekly for 4 weeks, then increased to 1.2 g once weekly for 1 week, followed by maintenance 1.2 g every 12–16 days, consider ... This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Soliris ...